

## PRESS RELEASE

# Piramal Pharma Solutions Announces Winner of its Winter 2022 Award for Excellence in Patient Centricity

- *Grangemouth, UK site Patient Awareness Council wins the Award*
- *Site PAC recognized for its program comparing ADC treatments to conventional cancer drugs*
- *Award recognizes the hands-on application of Patient Centricity at one of the company's fourteen global sites*

**Mumbai, India | March 15, 2022:** Piramal Pharma Limited's Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced that the company's site in Grangemouth, UK, has been selected as the winner of the most recent PPS Award for Excellence in Patient Centricity.



The award, which is given out twice per year, goes to the Patient Awareness Council (PAC) at a PPS site in recognition of a specific program they initiated related to Patient Centricity. A core ideology of the company, Patient Centricity is built upon the principal that understanding the needs of patients and building an organization that is dedicated to addressing those needs is foundational to the company. As part of the Patient Centricity onboarding initiative, employees at all fourteen of the company's sites around the world received dedicated training on how to embrace the concept and make the program a reality. Patient Awareness Councils were formed at each site for the purpose of driving the idea forward at a local level.



According to **Stuart Needleman, Chief Patient Centricity Officer at Piramal Pharma Solutions**, “We received another strong set of nominations from Patient Awareness Councils for our latest Excellence in Patient Centricity Award. After much debate, senior management selected the Lunch and Learn project at Grangemouth as the winner from all the submissions. It received high marks for its concept, execution, and relevance to our goal of being a patient-centric CDMO.”

The Grangemouth PAC’s Lunch and Learn sessions were designed to raise knowledge of how the site’s expertise in developing and manufacturing antibody-drug conjugates (ADCs) relates to patients, the site staff, and the local community. In a presentation attended by close to half of the total staff in Grangemouth, the differences between ADCs and conventional therapies and why the modality has fewer side effects and improved outcomes in late-stage cancers were discussed. An abridged version of the presentation was given to members of a local Rotary club to raise awareness of the work done at Grangemouth and the benefits of ADCs.

PPS Grangemouth is recognized around the world as a leader in the development and manufacture of antibody-drug conjugates and other bioconjugates. The facility boasts two significant ADC capabilities: fit-for-purpose rapid development for early clinical materials and robust, scalable late phase development to support pivotal trials and commercial launch. By combining these skills with offerings from our other thirteen global facilities, including fill/finish, payloads, and peptides, we can provide integrated ADC services to customers looking for fast, simplified solutions.



**Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions** said, “The timing of this award is significant, since we recently announced a major capacity expansion of the Grangemouth facility. We are investing in new manufacturing suites that will more than double our ADC production capacity and meet demand for commercial ADCs, strengthening our ability to service customers throughout the entire drug lifecycle.”

\*\*\*

**About Piramal Pharma Solutions:**

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. PPS also offers development and manufacturing services for biologics including vaccines, gene therapies, and monoclonal antibodies, made possible through Piramal Pharma Limited's investment in Yapan Bio Private Limited. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.

For more information please visit: [www.piramalpharmasolutions.com](http://www.piramalpharmasolutions.com) | [Twitter](#) | [LinkedIn](#)

**About Piramal Pharma Ltd.**

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network over 100 countries. PPL includes: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business, selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovator and generic companies. PCC's complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The Indian Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the Indian consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received growth equity investment from the Carlyle Group.

For more information visit: [www.piramal.com](http://www.piramal.com) | [Facebook](#) | [Twitter](#) | [LinkedIn](#)

---

**For Media Queries**

Rajiv Banerjee  
Corporate Communications  
[Rajiv.Banerjee@piramal.com](mailto:Rajiv.Banerjee@piramal.com)

**For Investors**

Hitesh Dhadha/Mayank Kumar  
Investor Relations  
[investor.relations@piramal.com](mailto:investor.relations@piramal.com)